Brief: Longeveron® Announces U.S. FDA Approval Of Ind Application
08/07/2025 15:23
July 8 (Reuters) - Longeveron Inc LGVN.O: LONGEVERON® ANNOUNCES U.S. FDA APPROVAL OF IND APPLICATION FOR A PHASE 2 PIVOTAL REGISTRATION STUDY EVALUATING LAROMESTROCEL AS A TREATMENT OF PEDIATRIC DILATED CARDIOMYOPATHY (DCM) LONGEVERON INC - PHASE 2 TRIAL INITIATION EXPECTED IN FIRST HALF OF 2026 Source text: ID:nGNXJ3bvK Further company coverage: LGVN.O ((((Reuters.Briefs@thomsonreuters.com));))